SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:oru-99515"
 

Search: onr:"swepub:oai:DiVA.org:oru-99515" > Total Cardiovascula...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Szarek, MichaelCPC Clinical Research, Aurora, CO, USA; Department of Medicine, University of Colorado, Aurora, CO, USA; SUNY Downstate Health Sciences University, Brooklyn, NY, USA (author)

Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • John Wiley & Sons,2022
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-99515
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-99515URI
  • https://doi.org/10.1161/JAHA.122.025504DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: Peripheral artery disease (PAD) is associated with heightened risk for major adverse cardiovascular and limb events, but data on the burden of risk for total (first and potentially subsequent) events, and the association with polyvascular disease, are limited. This post hoc analysis of the EUCLID (Examining Use of Ticagrelor in Peripheral Artery Disease) trial evaluated total cardiovascular and limb events among patients with symptomatic PAD, overall and by number of symptomatic vascular territories.Methods and Results: In the EUCLID trial, patients with symptomatic PAD (lower extremity revascularization >30 days before randomization or ankle-brachial index ≤0.80) were randomized to treatment with ticagrelor or clopidogrel. Relative effects on total events (cardiovascular death; nonfatal myocardial infarction and ischemic stroke; acute limb ischemia, unstable angina, and transient ischemic attack requiring hospitalization; coronary, carotid, and peripheral revascularization procedures; and amputation for symptomatic PAD) were summarized by hazard ratios (HRs), whereas absolute risks were estimated by incidence rates and mean cumulative functions. Among 13 885 randomized patients, 7600 total cardiovascular and limb events occurred during a median 2.7 years of follow-up, translating to 60.0 and 62.5 events per 100 patients through 3 years for the ticagrelor and clopidogrel groups, respectively (HR, 0.96; 95% CI, 0.89-1.03; P=0.27). Among 1393 patients with disease in 3 vascular territories, event accrual rates through 3 years for the ticagrelor and clopidogrel groups were 87.3 and 97.7 events per 100 patients, respectively. Absolute risk reductions for ticagrelor relative to clopidogrel at 3 years were -0.2, 6.7, and 10.3 events per 100 patients for 1, 2, and 3 affected vascular territories, respectively (Pinteraction=0.09).Conclusions: Patients with symptomatic PAD have nearly double the number of total events than first events, with rates reflecting the number of affected vascular territories. These findings highlight the clinical relevance of quantifying disease burden in terms of total events and the need for long-term preventive treatments in high-risk patient populations. Registration URL: https://clinicaltrials.gov/; Unique identifier: NCT01732822.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Hess, ConnieCPC Clinical Research, Aurora, CO, USA; Department of Medicine, University of Colorado, Aurora, CO, USA (author)
  • Patel, Manesh R.Duke Clinical Research Institute, Durham, NC, USA; Division of Cardiology, Duke University Medical Center, Durham, NC, USA (author)
  • Jones, W. SchuylerDuke Clinical Research Institute, Durham, NC, USA; Division of Cardiology, Duke University Medical Center, Durham, NC, USA (author)
  • Berger, Jeffrey S.New York University School of Medicine, New York, NY, USA (author)
  • Baumgartner, IrisSwiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland; University of Bern, Bern, Switzerland (author)
  • Katona, BrianAstraZeneca Gaithersburg, Gaithersburg, MD, USA (author)
  • Mahaffey, Kenneth W.Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA, USA (author)
  • Norgren, Lars,1942-Örebro universitet,Institutionen för medicinska vetenskaper(Swepub:oru)lsnn (author)
  • Blomster, JuusoTurku University Hospital, Turku, Finland (author)
  • Rockhold, Frank W.Duke Clinical Research Institute, Durham, NC, USA (author)
  • Hsia, JudithCPC Clinical Research, Aurora, CO, USA; Department of Medicine, University of Colorado, Aurora, CO, USA (author)
  • Fowkes, F. Gerry R.Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK (author)
  • Bonaca, Marc PCPC Clinical Research, Aurora, CO, USA; Department of Medicine, University of Colorado, Aurora, CO, USA (author)
  • CPC Clinical Research, Aurora, CO, USA; Department of Medicine, University of Colorado, Aurora, CO, USA; SUNY Downstate Health Sciences University, Brooklyn, NY, USACPC Clinical Research, Aurora, CO, USA; Department of Medicine, University of Colorado, Aurora, CO, USA (creator_code:org_t)

Related titles

  • In:Journal of the American Heart Association: John Wiley & Sons11:112047-9980

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view